Co-Authors
This is a "connection" page, showing publications co-authored by JACK A ROTH and BINGBING DAI.
Connection Strength
1.716
-
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One. 2015; 10(6):e0123967.
Score: 0.515
-
KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 2013 Sep 01; 73(17):5532-43.
Score: 0.451
-
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011 May 15; 71(10):3658-68.
Score: 0.385
-
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget. 2017 Dec 08; 8(64):107621-107629.
Score: 0.153
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29; 5(11):e14124.
Score: 0.094
-
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016 Jan 19; 7(3):3548-58.
Score: 0.034
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.031
-
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013 Dec; 12(12):2864-73.
Score: 0.029
-
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012 May 15; 83(10):1456-64.
Score: 0.026